The FDA added it to injectable semaglutide in January 2025, and it climbs the dose axis like everything else. Burning or tingling skin tracks the dose, not the weight lost, and an active-comparator study put the risk about twice that of another weight-loss drug. The mechanism is unsettled: the tempting "it is the drugs signaling arm" story is ruled out, because the strongest GLP-1 signaler in the class carries no such signal
Analyst 141, 28612864 (2016)
Tumor imaging and therapy using radiolabeled somatostatin analogues
As previously reported, glutathione (GSH) can reduce disulfide bonds in tumor cells to form sulfhydryl groups, which not only depletes GSH but also facilitates drug release from PEG-S-S-PLA nano-micelles
For the reconstitution math common to every peptide, see the main peptide calculator
10.1016/j.expneurol.2013.03.017 49 FineJ